Polyethyleneglycol-modified polypeptide capable of inhibiting interleukin-6 and application thereof

Abstract

The invention relates to the field of medicine, particularly a polyethyleneglycol-modified polypeptide capable of inhibiting interleukin-6 and preventing and treating rheumatoid arthritis. The sequence is mPEG-SC20k-VFLCGLLVMAC which is a brand-new sequence. The polypeptide capable of inhibiting interleukin-6 can be used for treating rheumatoid arthritis, and has potential value in developing new drugs.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to an interleukin-6 polypeptide inhibitor for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in my country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling on the back of the wrist) as...

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long

The research on PEG modification of synthetic small molecule peptides started late, but it has attracted the attention of many researchers